# HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Study · id `cardio:ct-nct07123779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07123779](<https://clinicaltrials.gov/study/NCT07123779>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07123779

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.

## Technical summary

Registry record NCT07123779. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-21 (actual); primary completion 2029-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT07123779, source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)
- Started: 2026-10-21 (actual) (ClinicalTrials.gov record NCT07123779, source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2029-01 (anticipated) (ClinicalTrials.gov record NCT07123779, source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)
- Completion: 2030-01 (anticipated) (ClinicalTrials.gov record NCT07123779, source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07123779, source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07123779-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
- Condition: Pulmonary Hypertension
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Biological): HS235
- Intervention (Other): Placebo
- Lead sponsor: 35Pharma Inc., a GSK company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: b751b97e7acf8af347009d699d19c661c39a25915ee0e6d87005c945fe3a6e39
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
